Compositions including triciribine and one or more platinum compounds and methods of use thereof

A method for treating a subject having a tumor or cancer, which tumor or cancer overexpresses AKT kinase comprising:

• (i) determining whether the subject has a tumor or cancer that overexpresses AKT kinase;
• (ii) if said subject has a tumor or cancer that overexpresses AKT kinase,
• a. administering to said subject:
• i. at least one compound of formula I selected from the group consisting of the following compounds:
• wherein each R2′, R3′, and R5′ is independently hydrogen;
• optionally substituted phosphate or phosphonate;
• mono-, di-, or triphosphate;
• acyl;
• lower acyl;
• alkyl;
• lower alkyl;
• amide;
• sulfonate ester;
• alkyl sulfonate ester;
• arylalkyl sulfonate ester;
• sulfonyl;
• methanesulfonyl;
• benzyl sulfonyl, wherein the phenyl group of said benzyl is optionally substituted with one or more halo, hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate;
• optionally substituted arylsulfonyl;
• a lipid;
• phospholipid;
• an amino acid;
• a carbohydrate;
• a peptide;
• or cholesterol;
• or other pharmaceutically acceptable leaving group that, in vivo, provides a compound of said formula I wherein R2′, R3′ or R5′ is independently H or mono-, di- or tri-phosphate;
• wherein Rx and Ry are independently hydrogen;
• optionally substituted phosphate;
• acyl;
• lower acyl;
• amide;
• alkyl;
• lower alkyl;
• aromatic;
• polyoxyalkylene;
• polyethyleneglycol;
• optionally substituted arylsulfonyl;
• a lipid;
• a phospholipid;
• an amino acid;
• a carbohydrate;
• a peptide;
• or cholesterol;
• or other pharmaceutically acceptable leaving group;
• and
• wherein R1 and R2 each are independently H, optionally substituted straight chained, branched or cyclic alkyl, lower alkyl, alkenyl, or alkynyl, CO-alkyl, CO-alkenyl, CO-alkynyl, CO-aryl or heteroaryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, sulfonyl, alkylsulfonyl, arylsulfonyl, or aralkylsulfonyl;
• ii. one or more platinum compounds of formula V,
• wherein R1, R2, R3 and R4 are each independently hydrogen, optionally substituted amine, aromatic amine, heteroaromatic amine, optionally substituted straight chained, branched or cyclic alkyl, aromatic, heteroaromatic or cyclic ring formed among R1, R2, R3 and R4;
• R5 and R6 are each independently halogen, optionally substituted alkoxy, optionally substituted ester, optionally substituted alkyl amine, aromatic amine, heteroaromatic amine;
• and
• iii. a pharmaceutically acceptable carrier.